A better roadmap for beating a deadly leukemia

Acute myeloid leukemia, or AML, is the most common acute blood cancer in adults — and one of the most difficult to treat. Scientists at Oregon Health & Science University have discovered a...

Detecting tumor responses before they become deadly

Targeted cancer therapies can be stunningly effective at blocking specific, cancer-driving signals. But all too often, tumors develop resistance by switching to alternative signaling pathways to...

Jamming fat metabolism stops blood cancer cells

Targeted cancer therapies work by blocking specific, cancer-driving mutations. But in a new laboratory study, researchers show that cancers driven by several different mutations can all be stopped by...

Clinical trial elevates new target for fighting cancers

Researchers have verified a much-needed new target for treating cancers that often become resistant to existing therapies and become deadly. In an early-phase clinical trial, the researchers tested...

Overcoming drug resistance to stop a deadly blood cancer

Cancer researchers have discovered a potential way to make targeted therapy drugs more effective and longer lasting for people with acute myeloid leukemia, or AML. The scientists showed how it is...

Unlocking the combination to target evasive kidney cancers

Roughly one in four people with kidney cancer have a type that does not respond to targeted therapy drugs, leaving no proven treatment options for those whose tumors have started to...

Perturbed tumors reveal their secrets

A trove of freely accessible cancer data helps researchers find new combination treatments. Targeted cancer therapies work by blocking a specific cancer-driving signal, thus limiting harm to healthy...

For veterans with prostate cancer, a new center of excellence in Oregon

VA Portland Health Care System and OHSU are launching a precision oncology center of excellence supported by the Prostate Cancer Foundation. On Veteran's Day, the foundation announced $5 million in...